Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients

High Blood Pressure and Cardiovascular Prevention

Volumn 24, Issue 4, 2017, Pages 393-400

  Dell’Oro, Raffaella ^a   Maloberti, Alessandro ^a   Nicoli, Francesco ^a   Villa, Paolo ^a   Gamba, Pierluigi ^a   Bombelli, Michele ^a   Mancia, Giuseppe ^a   Grassi, Guido ^a,b  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Arterial stiffness; Endothelial function; Inhibitors of dipeptidyl peptidase 4; Saxagliptin; Shear stress; Ultrasonography

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SAXAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADD ON THERAPY; ADULT; ANTHROPOMETRY; AORTA; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MONITORING; BRACHIAL ARTERY; CARDIOVASCULAR EFFECT; CLINICAL ARTICLE; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FLOW MEDIATED DILATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMODYNAMICS; HUMAN; LONG TERM CARE; METABOLIC PARAMETERS; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM; VASODILATATION; ANALOGS AND DERIVATIVES; ARTERIAL STIFFNESS; BLOOD; CAROTID ARTERY; CASE CONTROL STUDY; COMPLICATION; CONVALESCENCE; DIABETIC ANGIOPATHY; DIAGNOSTIC IMAGING; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; TIME FACTOR; TREATMENT OUTCOME;

ADAMANTANE; BIOMARKERS; BLOOD GLUCOSE; CAROTID ARTERIES; CAROTID INTIMA-MEDIA THICKNESS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULSE WAVE ANALYSIS; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 85030873258     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.1007/s40292-017-0215-2     Document Type: Article

References (30)

1. Schiavoni M, Cosentino F, Camici G, Luescher TF. Daibetes and endothelial dysfunction. What is the culprit? High Blood Press Cardiovasc Prev. 2007;14:5–10.
2. Widlansky ME, Gocke N, Keaney JF, Vita JA. The clinical implication of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149–60.
3. Park CM, Tillin T, March K, Jones S, Whincup PH, Mayet J, Chaturdedy N, Hughes AD. Adverse effcts of diabetes and hyperglycaemia on arterial stiffness in european, south asian and african caribbeans in the SABRE study. J Hypertens. 2016;34:282–9.
4. Kotb NA, Gaber R, Salah W, Elhendy A. Relations among glycemic control, circulating endothelial cells, nitric oxide, and flow-mediated dilation in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:460–5.
5. Eriksson L, Nystrom T. Antidiabetic agents and endothelial dysfunction—beyond glucose control. Basic Clin Pharmacol Toxicol. 2015;117:15–25.
6. Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens. 2009;3:245–59.
7. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol. 2013;10:73–84.
8. Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H. Dipeptidyl peptidase-4 inhibitor, sitagliptin, impoves endothelial dysfunction in association with its antiinflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77:1337–44.
9. van Poppel PCM, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium-dependent vasodilation in type 2 diabetes. Diabetes Care. 2010;34:2072–7.
10. Duvnjak L, Blasov K. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabets mellitus. Diabetol Metab Syndr. 2016;8:26.
11. Ott C, Raff U, Schmidt S, Kistner I, Friedrich S, Bramiage P, Harazny JM, Schmieder R. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol. 2014;13:19.
12. Sega R, Cesana G, Milesi C, Grassi G, Zanchetti A, Mancia G. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension. 1997;30:1–6.
13. Salvi P, Lio G, Labat C, Ricci E, Pannier B, Benetos A. Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: the PulsePen device. J Hypertens. 2004;22:2285–93.
14. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H. European network for non-invasive investigation of large arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–605.
15. The Reference Values for Arterial Stiffness’ Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: establishing normal and reference values. Eur Heart J. 2010;31:2338–50.
16. Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens. 2007;25:2463–70.
17. Maloberti A, Meani P, Varrenti M, Giupponi L, Stucchi M, Vallerio P, Giannattasio C. Structural and functional abnormalities of carotid artery and their relation with EVA phenomenon. High Blood Press Cardiovasc Prev. 2015;22:373–9.
18. Greyling A, van Mil AC, Zock PL, Green DJ, Ghaidoni L, Thijssen DH, TIFN International Working Group on Flow Mediated Dilation. Adherence to guidelines strongly improves reproducibility of brachial artery flow-mediated dilation. Atherosclerosis. 2016;248:196–202.
19. Barbieri M, Rizzo MR, Marfella R, Boccardi V, Esposito A, Pansini A, Paolisso G. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013;227:349–54.
20. Ishikawa S, Shimano M, Watarai M, Koyasu M, Uchikawa T, Ishii H, Inden Y, Takemoto K, Murohara T. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus. Am J Cardiol. 2014;114:384–8.
21. Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H, Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) Trial. Alogliptin, a dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39:139–48.
22. Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H, Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) Trial. Sitagliptin attenuates the progression of carotid intima-media thickening in Insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial. Diabetes Care. 2016;39:455–64.
23. Fisslthaler B, Benzing T, Busse R, Fleming I. Insulin enhances the expression of the endothelial nitric oxide synthase in native endothelial cells: a dual role for Akt and AP-1. Nitric Oxide. 2003;8:253–61.
24. Birnbaum Y, Bajaj M, Qian J, Ye Y. Dipeptidyl peptidase-4 inhibition by Saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res Care. 2016;4:e000227.
25. Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, Miura D, Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P) Hoxidase pathway in human aortic endothelial cells. Atherosclerosis. 2014;232:156–64.
26. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013;125:7–20.
27. Zhang X, Zhao Q. Effects od dipeptidylpeptidase-4 inhibitors on blood pressure in patients with type-2 diabtes. A systematic review and meta-analyisis. J Hypertens. 2016;34:167–75.
28. Nilsson PM, Diez J. DPP-4 inhibition and blood pressure lowering in perspective. J Hypertens. 2016;34:184–7.
29. Kumarathurai P, Anholm C, Kristiansen OK, Nielsen OW, Hauggard SB, Sajadieh A. The effect of glucagon-like peptide-1 receptor agonist liraglutide on 24-h blood pressure variation. A randomized double-blind placebo-controlled cross-over study. J Hypertens. 2016. doi:10.1097/01.hjh.0000491445.66874.a8.
30. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure. Evidence and limits. Circ Res. 2015;116:1034–45.